Nimbus Therapeutics

We’re thrilled to announce that Peter Tummino, PhD., has been appointed to President of R&D at Nimbus Therapeutics! Under Peter's leadership since 2019, our pipeline has grown significantly, including completion of the IND submission for our investigational non-covalent #WRN inhibitor NDI-219216, with plans to initiate clinical trial in 1H 2025. As President of R&D, Peter will continue to drive innovation across our portfolio from Discovery through Clinical Development. His deep expertise and vision have been instrumental in our success, and we're excited for this next chapter.

Next week, January 13-16, Nimbus will be at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. We’re honored that our CEO Jeb Keiper is kicking off the private track presentations on Monday, January 13 at 7:30am PT, where he will provide pipeline and personnel updates, as well as our anticipated milestones for 2025 and beyond. Learn more here: https://bit.ly/4gJh9cD #JPM25

We're excited to share how our computational chemistry team is accelerating drug discovery through machine learning in AWS for Healthcare & Life Sciences' latest customer story. Using #AWS SageMaker as part of our technology stack, we’ve built an MLOps pipeline that automates predictive models to design molecules with desired drug-like properties and accelerate the time from idea inception to clinic. Read about how our team combines expertise in #computationalchemistry and #machinelearning to advance our mission of designing breakthrough medicines for patients: https://lnkd.in/eFuMNAKy Amazon Web Services (AWS) #SageMaker

While precision medicine advances in genomics and rare diseases, we're witnessing an intriguing counter-trend: the rise of "mega blockbusters" - therapeutics that treat broad patient populations and generate over $10 billion in peak sales. Our Chief Business Officer Abbas Kazimi and SANTÉ Managing Director Omar H. Khalil recently co-authored an GEN Biotechnology article, examining how scientific breakthroughs in common disease pathways, advances in generative AI for multimodal drug design, and the unprecedented growth in obesity therapeutics are redefining drug development. Read more about how this shift could transform the future of pharmaceuticals: https://lnkd.in/eFb2P6eN

2024 was a momentous year for Nimbus Therapeutics. We expanded our pipeline, proudly watched our molecules advance internally and at Takeda, and celebrated our company's 15th anniversary. We were honored to be named once again as one of Boston Globe Media's 'Top Places to Work' as we welcomed new #Nimbi, including a class of talented summer interns from Project Onramp, and deepened our commitment to the Boston community through impactful work with local partners like the Pine Street Inn, Bottom Line, Boston Harbor Now and Life Science Cares Boston. Thank you to our employees, patients, partners, and supporters for another year of innovation. There's so much more to look forward to in 2025 – Happy New Year!

Last week marked one of our most cherished #Nimbi traditions – our annual Yankee Swap! Our team shared laughs, surprises, and time for connection while exchanging (and stealing) mystery gifts. These moments of camaraderie remind us of what makes our community so special. Warmest holiday wishes from our family at Nimbus to yours!

Thank you David Wild, and the In Vivo team, for spotlighting the pivotal role of disciplined portfolio management in drug development. At Nimbus Therapeutics, we've learned that innovation isn’t just about pursuing every opportunity—it’s about making tough, strategic choices: knowing when to pivot, redirect, or even stop. As I shared in the article, "Like your program, but love the portfolio." This philosophy has been central to our success and resilience as a company. By focusing our resources where they matter most, we’ve unlocked meaningful opportunities. Redirecting efforts to our #TYK2 inhibitor program led to our impactful collaboration with Takeda, while strategically pausing our #AMPK program paved the way for our partnership with Eli Lilly and Company. You can read the full article in Citeline Commercial below:

'Like your program, but love the portfolio' — this guiding principle at Nimbus reflects our commitment to strategic decision-making in drug development. Our Chief Business Officer Abbas Kazimi recently spoke with David Wild at In Vivo about the strategic value of "failing fast" in drug development. By identifying unsuccessful candidates early and decisively pivoting resources to higher-probability programs, we've built a strong portfolio and established valuable partnerships, including our landmark deal with Takeda and ongoing collaboration with Eli Lilly and Company. Abbas shared insights on how strategic portfolio management and decisive decision-making create value for scientists, investors, partners, and ultimately, patients. https://lnkd.in/eQkft46X

Next month, just ahead of the J.P. Morgan Healthcare Conference, our CEO Jeb Keiper will join a distinguished panel at the Longwood Healthcare Leaders San Francisco CEO event. The panel, “Impact & Importance of Company Culture” brings together industry leaders for an insightful discussion on Saturday January 11. Learn more: https://lnkd.in/esNkzCWY 

We’re honored to once again be named as one of Boston Globe Media’s ‘Top Places to Work’ for 2024. At Nimbus, our vibrant culture defines who we are. We’re driven by innovation, fueled by collaboration, and united in our mission to make breakthrough medicines for patients. This repeated honor reflects the passion and commitment of every team member who makes Nimbus such a special place to work. Read the official #TopPlacesToWork announcement: https://bit.ly/49pEvBd #WorkBoston